Back to top

Image: Bigstock

Zacks Market Edge Highlights: ExxonMobil, Meta Platforms, UnitedHealth Group, Biogen and NVIDIA

Read MoreHide Full Article

For Immediate Release

Chicago, IL – October 6, 2022 – Zacks Market Edge is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here:

Should You Sell Your FANGMAN Stocks?

Welcome to Episode #331 of the Zacks Market Edge Podcast.

  • (1:00) - Should You Continue To Invest In Growth Stocks?
  • (6:10) - Understanding FANG During A Down Market
  • (17:45) - Should You Be Buying The Dip Or Staying On The Sidelines?
  • (29:00) - Have A Plan That Works For Your Investment Timeframe
  • (34:50) - Episode Roundup: XOM, META, NVDA, MSFT, UNH, CNC, BIIB, LLY, ARKK

  Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life.

This week, Tracey is joined by Zacks Senior Strategist, Kevin Cook, to discuss their favorite topic: what should investors do as stocks sell-off?

Should you sell? Or add further to your positions?

What do you do with growth stocks? Do you sell your FANGMAN stocks, which are down anywhere from 10% to 50% from their highs?

Or do you do...nothing?

Exxon's Market Cap Overtakes Meta Platforms

This year, for the first time in 5 years, ExxonMobil's (XOM - Free Report) market cap has exceeded Meta Platforms (META - Free Report) , one of the FANGMAN stocks.

Meta Platforms shares have fallen 18.5% over the last 5 years as shares have plunged this year.

But ExxonMobil shares are now up 16% over the last 5 years after gaining 56% this year.

ExxonMobil has been a value stock for years. Meta Platforms was a growth stock, often listed among the top stocks as one of the "FANGMANs."

Is the tide turning in favor of value?

[As we talk about in the podcast, Kevin is reading the May 2022 book called Fossil Future by Alex Epstein. Tracey promised to link to it. You can find it on Amazon here.]

What's Working and What's Not

In addition to energy, investors have been fleeing to healthcare stocks for safety. Should you follow?

And they have been selling the big tech names, especially the semiconductors. Are the semi stocks oversold?

1.       UnitedHealth Group (UNH - Free Report)

UnitedHealth Group has been holding up during the 2022 sell-off. Shares are up 4.2% year-to-date while the S&P 500 is down 22.8%.

Over the last 5 years, UnitedHealth Group shares are up 164% compared to just 48.7% for the S&P 500.

UnitedHealth Group isn't cheap. It trades with a forward P/E of 23.6.

It also pays a dividend, but it is only yielding 1.3%.

Is it too late to hide out in UnitedHealth Group?

2.       Biogen (BIIB - Free Report)

Biogen shares popped 37% recently after it announced its Alzheimer's drug reduced cognitive decline by 27% compared to the placebo.

Shares of Biogen are up 11.5% year-to-date.

Biogen isn't that expensive, with a forward P/E of 16.1. It does not, however, pay a dividend.

Should investors be buying Biogen after the big pop?

3.       NVIDIA (NVDA - Free Report)

NVIDIA is one of the big winners of the "FANGMAN" stocks. Over the last 5 years, NVIDIA has gained 190%.

But NVIDIA shares have taken a big dive in 2022, falling 55.2%.

Shares of NVIDIA are still expensive at 35x. It now has a Zacks Rank of 5 (Strong Sell).

NVIDIA has been one of Kevin's favorite stocks. Is he buying it here on weakness?

What Else Should You Know About the Stock Market Sell-Off and Growth Stocks?

Tune into this week's podcast to find out.

Why Haven't You Looked at Zacks' Top Stocks?

Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.

See Stocks Free >>

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit information about the performance numbers displayed in this press release.

Published in